FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8103人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839583, encodeId=8fcb18395831d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准**遗传佝偻病药物burosumab, objectType=article, longId=135840, objectId=da96135840d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da96135840d3, replyNumber=0, likeNumber=77, createdTime=2018-09-23, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da96135840d3, moduleTitle=FDA批准**遗传佝偻病药物burosumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da96135840d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839534, encodeId=2c311839534e0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准应用程序治疗物质使用障碍, objectType=article, longId=113566, objectId=c9e611356664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9e611356664, replyNumber=0, likeNumber=68, createdTime=2018-04-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9e611356664, moduleTitle=FDA批准应用程序治疗物质使用障碍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9e611356664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839578, encodeId=f5d918395e80a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了Opdivo每四周一次的剂量, objectType=article, longId=132575, objectId=43221325e59a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43221325e59a, replyNumber=0, likeNumber=60, createdTime=2018-10-12, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43221325e59a, moduleTitle=FDA批准了Opdivo每四周一次的剂量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43221325e59a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839521, encodeId=a9511839521ee, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准新生儿磁共振成像装置, objectType=article, longId=106328, objectId=c77210632857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77210632857, replyNumber=0, likeNumber=61, createdTime=2017-10-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77210632857, moduleTitle=FDA批准新生儿磁共振成像装置, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77210632857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839586, encodeId=fa2618395863c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=72, createdTime=2018-12-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839542, encodeId=83d11839542d6, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准中枢性睡眠呼吸暂停新治疗方法, objectType=article, longId=115499, objectId=23fa11549973, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23fa11549973, replyNumber=0, likeNumber=64, createdTime=2018-01-27, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23fa11549973, moduleTitle=FDA批准中枢性睡眠呼吸暂停新治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23fa11549973)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839556, encodeId=849518395561f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗, objectType=article, longId=121902, objectId=67b612190234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67b612190234, replyNumber=0, likeNumber=73, createdTime=2018-07-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67b612190234, moduleTitle=CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67b612190234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839599, encodeId=75e11839599fd, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=JACC：FDA批准心血管药物的临床试验：女性患者的代表性问题, objectType=article, longId=141182, objectId=30961411820b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30961411820b, replyNumber=0, likeNumber=47, createdTime=2019-04-10, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30961411820b, moduleTitle=JACC：FDA批准心血管药物的临床试验：女性患者的代表性问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30961411820b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839549, encodeId=f76918395499b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准, objectType=article, longId=121092, objectId=76a6121092e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76a6121092e6, replyNumber=0, likeNumber=60, createdTime=2018-10-22, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76a6121092e6, moduleTitle=勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76a6121092e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839557, encodeId=4fec183955e89, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗, objectType=article, longId=122001, objectId=be1312200102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be1312200102, replyNumber=0, likeNumber=59, createdTime=2017-12-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be1312200102, moduleTitle=CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be1312200102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839566, encodeId=1906183956678, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准无需进行手指点刺的血糖监测, objectType=article, longId=125137, objectId=405312513e51, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405312513e51, replyNumber=0, likeNumber=0, createdTime=2018-11-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405312513e51, moduleTitle=FDA批准无需进行手指点刺的血糖监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405312513e51)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839587, encodeId=a210183958ee0, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=BMJ：NCCN推荐抗癌药物适应症的范围超过了FDA批准！, objectType=article, longId=137032, objectId=6efe13e032bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6efe13e032bd, replyNumber=0, likeNumber=65, createdTime=2019-03-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6efe13e032bd, moduleTitle=BMJ：NCCN推荐抗癌药物适应症的范围超过了FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6efe13e032bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839575, encodeId=0a1218395e55a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准强生前列腺癌新疗法可延长生存期超2年, objectType=article, longId=130592, objectId=0bf3130592e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bf3130592e5, replyNumber=0, likeNumber=72, createdTime=2018-05-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bf3130592e5, moduleTitle=FDA批准强生前列腺癌新疗法可延长生存期超2年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bf3130592e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839564, encodeId=600718395642d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准年度第44款新药用于生长激素缺乏症, objectType=article, longId=124355, objectId=2f411243553a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f411243553a, replyNumber=0, likeNumber=70, createdTime=2018-05-08, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f411243553a, moduleTitle=FDA批准年度第44款新药用于生长激素缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f411243553a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839526, encodeId=ade01839526c7, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=阿斯利康卵巢癌新药获FDA批准！, objectType=article, longId=110453, objectId=cdf211045387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf211045387, replyNumber=0, likeNumber=119, createdTime=2018-02-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf211045387, moduleTitle=阿斯利康卵巢癌新药获FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdf211045387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839577, encodeId=901218395e7a9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准OTIPRIO治疗急性外耳道炎, objectType=article, longId=131473, objectId=e8771314e3c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8771314e3c0, replyNumber=0, likeNumber=47, createdTime=2018-05-02, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8771314e3c0, moduleTitle=FDA批准OTIPRIO治疗急性外耳道炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8771314e3c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839546, encodeId=b97c183954699, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准远程医疗方案对植入人工耳蜗进行编程, objectType=article, longId=120644, objectId=73dd120644b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73dd120644b0, replyNumber=0, likeNumber=74, createdTime=2018-02-27, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73dd120644b0, moduleTitle=FDA批准远程医疗方案对植入人工耳蜗进行编程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73dd120644b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839511, encodeId=614118395110b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准用于过敏性结膜炎的局部滴眼液, objectType=article, longId=100601, objectId=0a8d100601af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a8d100601af, replyNumber=0, likeNumber=71, createdTime=2018-03-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a8d100601af, moduleTitle=FDA批准用于过敏性结膜炎的局部滴眼液, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a8d100601af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839567, encodeId=1f86183956ef3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Gastroenterology：FDA批准减肥药物长期心脏代谢风险研究, objectType=article, longId=125552, objectId=5051125552f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5051125552f1, replyNumber=0, likeNumber=69, createdTime=2018-07-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5051125552f1, moduleTitle=Gastroenterology：FDA批准减肥药物长期心脏代谢风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5051125552f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839535, encodeId=dc20183953501, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准携带一次性帽的十二指肠镜, objectType=article, longId=113701, objectId=ee75113e0128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee75113e0128, replyNumber=0, likeNumber=59, createdTime=2018-02-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee75113e0128, moduleTitle=FDA批准携带一次性帽的十二指肠镜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee75113e0128)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准**遗传佝偻病药物burosumab

2018-09-23

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准应用程序治疗物质使用障碍

2018-04-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了Opdivo每四周一次的剂量

2018-10-12

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准新生儿磁共振成像装置

2017-10-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-12-10

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准中枢性睡眠呼吸暂停新治疗方法

2018-01-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CFDA批准上市Votrient®（培唑帕尼），用于晚期肾细胞癌患者治疗

2018-07-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

JACC：FDA批准心血管药物的临床试验：女性患者的代表性问题

2019-04-10

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

勃林格殷格翰泰毕全®（达比加群酯）新适应症获CFDA批准

2018-10-22

bugit (审核中...)

前往app查看评论内容

#FDA批准#

CFDA批准上市泰瑞沙®（甲磺酸奥希替尼片）审评概述，用于非小细胞性肺癌(NSCLC)成人患者的治疗

2017-12-21

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准无需进行手指点刺的血糖监测

2018-11-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

BMJ：NCCN推荐抗癌药物适应症的范围超过了FDA批准！

2019-03-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准强生前列腺癌新疗法可延长生存期超2年

2018-05-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准年度第44款新药用于生长激素缺乏症

2018-05-08

bugit (审核中...)

前往app查看评论内容

#FDA批准#

阿斯利康卵巢癌新药获FDA批准！

2018-02-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准OTIPRIO治疗急性外耳道炎

2018-05-02

仁医06 (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准远程医疗方案对植入人工耳蜗进行编程

2018-02-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准用于过敏性结膜炎的局部滴眼液

2018-03-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Gastroenterology：FDA批准减肥药物长期心脏代谢风险研究

2018-07-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准携带一次性帽的十二指肠镜

2018-02-20

科室
- - 订阅+
  - 更多科室
工具
服务